Related Experiment Video
Updated: Jun 21, 2025
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
A targeting nanoplatform for chemo-photothermal synergistic therapy of small-cell lung cancer
Moli Yin1,2, Lei Liu2, Yu Yan3
1National and Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Abstract:
The precise delivery of drugs to tumor sites and the thermoresistance of tumors remain major challenges in photothermal therapy (PTT). Somatostatin receptor 2 (SSTR2) is proposed as an ideal target for the precise treatment of SCLC. We developed a targeting nano-drug delivery system comprising anti-SSTR2 monoclonal antibody (MAb) surface-modified nanoparticles co-encapsulating Cypate and gambogic acid (GA). The formed SGCPNs demonstrated excellent monodispersity, physiological stability, preferable biocompatibility, and resultant efficient photothermal conversion efficacy. SGCPNs were quickly internalized by SSTR2-overexpressing SCLC cells, triggering the release of GA under acidic and near-infrared (NIR) laser irradiation environments, leading to their escape from lysosomes to the cytosol and then diffusion into the nucleus. SGCPNs can not only decrease the cell survival rate but also inhibit the activity of heat shock protein 90 (HSP90). SGCPNs can be precisely delivered to xenograft tumors of SSTR2-positive SCLC in vivo. Upon NIR laser irradiation, therapy of SGCPNs showed significant tumor regression. In conclusion, SGCPNs provide a new chemo-photothermal synergistic treatment strategy for targeting SCLC.
Insights
This study introduces a novel nanoparticle system for precise small cell lung cancer (SCLC) treatment. The targeted nanoparticles combine chemotherapy and photothermal therapy, significantly reducing tumor size in vivo.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Photothermal therapy (PTT) faces challenges in precise drug delivery and overcoming tumor thermoresistance.
- Somatostatin receptor 2 (SSTR2) is a promising target for small cell lung cancer (SCLC) treatment.
Purpose of the Study:
- To develop a targeted nano-drug delivery system for synergistic chemo-photothermal therapy in SCLC.
- To evaluate the efficacy of the novel system in vitro and in vivo.
Main Methods:
- Development of SSTR2-targeted nanoparticles (SGCPNs) co-encapsulating Cypate and gambogic acid (GA).
- Assessment of SGCPN characteristics, including monodispersity, stability, biocompatibility, and photothermal conversion.
- Evaluation of SGCPN internalization, drug release, and therapeutic effects in SCLC cells and xenograft tumors.
Main Results:
- SGCPNs exhibited excellent physicochemical properties and efficient photothermal conversion.
- SGCPNs were effectively internalized by SCLC cells, releasing GA in response to acidic conditions and near-infrared (NIR) laser irradiation.
- The treatment demonstrated decreased cell survival, inhibited heat shock protein 90 (HSP90) activity, and significant tumor regression in vivo.
Conclusions:
- SGCPNs offer a promising targeted nano-drug delivery system for SCLC.
- The developed system provides a novel chemo-photothermal synergistic treatment strategy.
- This approach addresses challenges in precise drug delivery and tumor thermoresistance for SCLC therapy.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...